These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 24322665)
21. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Urato AC Obstet Gynecol; 2008 Sep; 112(3):703. PubMed ID: 18757678 [No Abstract] [Full Text] [Related]
22. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia. Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838 [No Abstract] [Full Text] [Related]
23. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. Laass MW; Straub S; Chainey S; Virgin G; Cushway T BMC Gastroenterol; 2014 Oct; 14():184. PubMed ID: 25326048 [TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Grimmelt AC; Cohen CD; Fehr T; Serra AL; Wuethrich RP Clin Nephrol; 2009 Feb; 71(2):125-9. PubMed ID: 19203504 [TBL] [Abstract][Full Text] [Related]
26. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Bregman DB; Morris D; Koch TA; He A; Goodnough LT Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357 [TBL] [Abstract][Full Text] [Related]
27. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137 [TBL] [Abstract][Full Text] [Related]
28. Phosphorus levels in children treated with intravenous ferric carboxymaltose. Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470 [No Abstract] [Full Text] [Related]
29. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Geisser P; Banké-Bochita J Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928 [TBL] [Abstract][Full Text] [Related]
30. Progress in intravenous iron treatment. Marx JJ Arzneimittelforschung; 2010; 60(6a):341-4. PubMed ID: 20648925 [No Abstract] [Full Text] [Related]
31. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. Qassim A; Mol BW; Grivell RM; Grzeskowiak LE Aust N Z J Obstet Gynaecol; 2018 Feb; 58(1):22-39. PubMed ID: 28921558 [TBL] [Abstract][Full Text] [Related]
32. Comment on: Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents. Schmugge M; Mattiello V; Hengartner H; von der Weid N; Renella R; Pediatr Blood Cancer; 2021 Mar; 68(3):e28726. PubMed ID: 32969156 [No Abstract] [Full Text] [Related]
33. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Befrits R; Wikman O; Blomquist L; Hjortswang H; Hammarlund P; Bajor A; Klintman D; Blom H Scand J Gastroenterol; 2013 Sep; 48(9):1027-32. PubMed ID: 23889159 [TBL] [Abstract][Full Text] [Related]
34. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. García-López S; Bocos JM; Gisbert JP; Bajador E; Chaparro M; Castaño C; García-Erce JA; Gomollón F Blood Transfus; 2016 May; 14(2):199-205. PubMed ID: 27177405 [TBL] [Abstract][Full Text] [Related]
35. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970 [TBL] [Abstract][Full Text] [Related]
36. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Wolf M; Koch TA; Bregman DB J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057 [TBL] [Abstract][Full Text] [Related]
37. Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure. Prats M; Font R; García-Ruiz C; Cabré C; Muñoz-Cortés M; Nogués MR; Jariod M; Romeu M; Martínez-Vea A Nefrologia; 2013; 33(3):355-61. PubMed ID: 23640119 [TBL] [Abstract][Full Text] [Related]
38. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia. Amarnani R; Travis S; Javaid MK Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323 [No Abstract] [Full Text] [Related]
39. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092 [TBL] [Abstract][Full Text] [Related]
40. Fatal anaphylactic reaction due to ferric carboxymaltose: A case report. Arici AM; Kumral Z; Gelal A; Akdeniz B Anatol J Cardiol; 2020 Aug; 24(2):115-117. PubMed ID: 32749249 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]